French recommendations for malignant pheochromocytomas and paragangliomas by the national ENDOCAN-COMETE network
Bull Cancer. 2023 Aug 10:S0007-4551(23)00297-7. doi: 10.1016/j.bulcan.2023.06.002. Online ahead of print.ABSTRACTPheochromocytomas and paragangliomas are rare neuroendocrine tumors, developed respectively in the adrenal medulla and in extra-adrenal locations. Their malignancy is defined by the presence of distant metastases. Forty percent of them are inherited and can be part of different hereditary syndromes. Their management is ensured in France by the multidisciplinary expert centers of the ENDOCAN-COMETE national network "Cancers of the Adrenal gland", certified by the National Cancer Institute and discussed within mul...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Christelle de la Fouchardi ère Magalie Haissaguerre Myriam Decaussin-Petrucci Karine Renaudin Fr éderic Deschamps Eric Miralli é Thibaut Murez Fran çois Pattou Laurence Rocher Pierre-Henri Savoie Matthieu Faron David Taieb Antoine Tabarin J érôme Be Source Type: research

Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : Diagnostic histomoléculaire des carcinomes de l'endomètre
Bull Cancer. 2023 Jun;110(6S):6S10-6S19. doi: 10.1016/S0007-4551(23)00330-2.ABSTRACTFrench recommendations for clinical practice Nice-Saint-Paul de Vence 2022-2023: histomolecular diagnosis of endometrial carcinomas The characterisation of endometrial carcinomas has been recently modified and enriched by molecular classification, the integration of which now impacts therapeutic decisions on whether adjuvant therapy should be administered or not in localized tumors, and influences treatment selection in advanced disease. Mandatory information includes histological type according to WHO 2020 classification, histological grad...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Corinne Jeanne Isabelle Treilleux Marie-Aude Le Fr ère-Belda J érôme Alexandre Florence Joly Etienne Rouleau Source Type: research

Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : prise en charge du cancer de l'endomètre localisé
Bull Cancer. 2023 Jun;110(6S):6S20-6S33. doi: 10.1016/S0007-4551(23)00331-4.ABSTRACTRecommendations for clinical practice, Nice/Saint-Paul-de-Vence 2022-2023: Management of localized endometrial cancer Endometrial cancer is the most frequent gynecological cancers in industrialized countries and its incidence increases. The newmolecularclassification allows determination of the risk of recurrence and helps orienting therapeutic management. Surgery remains the cornerstone of treatment. Minimally invasive approach must be preferred for stages I and II. Surgery includes hysterectomy with bilateral adnexectomy, sentinel lymph n...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Alejandra Mart ínez Cyrus Chargari Elsa Kalbacher Anne-Lise Gaillard Alexandra Leary Martin Koskas Nicol ás Chopin Anne-Agathe Serre Anne-Claire Hardy-Bessard Ch érif Akladios Fabrice Lecuru Source Type: research

Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : Prise en charge du cancer de l'endomètre métastatique et/ou en rechute
Bull Cancer. 2023 Jun;110(6S):6S34-6S43. doi: 10.1016/S0007-4551(23)00332-6.ABSTRACTRecommendations for clinical practice Nice/Saint-Paul-de-Vence 2022-2023 : Management of advanced/relapsing endometrial cancer Since the first recommendations in 2020 concerning metastatic and/or relapsed endometrial cancer, new treatment options have shown a benefit on patients' life expectancy, justifying their update. In first line, the choice will be made between chemotherapy with carboplatin/paclitaxel or hormone therapy with progestin, depending on tumor characteristics (histological type, grade, expression of hormone receptors, rate ...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: J érôme Alexandre Marie-Aude Le Fr ère-Belda Antoine Angelergues Gwena ël Ferron Isabelle Treilleux Anne-Lise Gaillard Jean-S ébastien Frenel Beno ît You Etienne Rouleau Alain Lortholary Isabelle Ray-Coquard Florence Joly Pour le groupe GINECO Source Type: research

Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : Prise en charge du cancer du col de l'utérus avancé
Bull Cancer. 2023 Jun;110(6S):6S44-6S50. doi: 10.1016/S0007-4551(23)00333-8.ABSTRACTFrench recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2022-2023: Management of advanced cervical cancer The prognosis of cervical cancer remained pejorative until recently, first-line treatment consisting of platinum-based chemotherapy, associated with bevacizumab whenever possible, without any other therapeutic innovation for several years. However in 2022, immunotherapy appeared in the therapeutic landscape. Pembrolizumab can now be prescribed, thanks to the early access status granted by the HAS in September 2022, in pat...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Patricia Pautier Catherine Genestie Laurence Gladieff Jean-Emmanuel Kurtz Alain Lortholary Thibault de La Motte Rouge Anne-Lise Gaillard Anne Ducassou Coraline Dubot Etienne Rouleau Fabrice Narducci Sylvain Demontoy Christophe Hennequin Source Type: research

Prise en charge des carcinomes ovariens de haut grade s éreux et/ou endométrioïdes de stades avancés (III-IV) et testing HRD-BRCA en 2023 : actualisation selon les données publiées et/ou présentées en 2022
Bull Cancer. 2023 Jun;110(6S):6S5-6S9. doi: 10.1016/S0007-4551(23)00329-6.ABSTRACTManagement of high grade, serous and/or endometrioid, advanced (stages III-IV) ovarian carcinomas and HRD-BRCA testing in 2023: update according to data published/presented in 2022 Molecular analysis of ovarian carcinomas must be now systematically performed to determine BRCA1 and BRCA2 status as well as genomic instability score. Several types of tests are available. From a clinical perspective, new data from phase III clinical trials presented in 2022 confirm the key role of PARP inhibitors in first-line medical treatment of high-grade sero...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Fr édéric Selle Florence Joly Laurence Gladieff Karine Prulhi ère Alexandra Leary Elsa Kalbacher Etienne Rouleau Isabelle Ray-Coquard Source Type: research

French recommendations for malignant pheochromocytomas and paragangliomas by the national ENDOCAN-COMETE network
Bull Cancer. 2023 Aug 10:S0007-4551(23)00297-7. doi: 10.1016/j.bulcan.2023.06.002. Online ahead of print.ABSTRACTPheochromocytomas and paragangliomas are rare neuroendocrine tumors, developed respectively in the adrenal medulla and in extra-adrenal locations. Their malignancy is defined by the presence of distant metastases. Forty percent of them are inherited and can be part of different hereditary syndromes. Their management is ensured in France by the multidisciplinary expert centers of the ENDOCAN-COMETE national network "Cancers of the Adrenal gland", certified by the National Cancer Institute and discussed within mul...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Christelle de la Fouchardi ère Magalie Haissaguerre Myriam Decaussin-Petrucci Karine Renaudin Fr éderic Deschamps Eric Miralli é Thibaut Murez Fran çois Pattou Laurence Rocher Pierre-Henri Savoie Matthieu Faron David Taieb Antoine Tabarin J érôme Be Source Type: research

Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : Diagnostic histomoléculaire des carcinomes de l'endomètre
Bull Cancer. 2023 Jun;110(6S):6S10-6S19. doi: 10.1016/S0007-4551(23)00330-2.ABSTRACTFrench recommendations for clinical practice Nice-Saint-Paul de Vence 2022-2023: histomolecular diagnosis of endometrial carcinomas The characterisation of endometrial carcinomas has been recently modified and enriched by molecular classification, the integration of which now impacts therapeutic decisions on whether adjuvant therapy should be administered or not in localized tumors, and influences treatment selection in advanced disease. Mandatory information includes histological type according to WHO 2020 classification, histological grad...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Corinne Jeanne Isabelle Treilleux Marie-Aude Le Fr ère-Belda J érôme Alexandre Florence Joly Etienne Rouleau Source Type: research

Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : prise en charge du cancer de l'endomètre localisé
Bull Cancer. 2023 Jun;110(6S):6S20-6S33. doi: 10.1016/S0007-4551(23)00331-4.ABSTRACTRecommendations for clinical practice, Nice/Saint-Paul-de-Vence 2022-2023: Management of localized endometrial cancer Endometrial cancer is the most frequent gynecological cancers in industrialized countries and its incidence increases. The newmolecularclassification allows determination of the risk of recurrence and helps orienting therapeutic management. Surgery remains the cornerstone of treatment. Minimally invasive approach must be preferred for stages I and II. Surgery includes hysterectomy with bilateral adnexectomy, sentinel lymph n...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Alejandra Mart ínez Cyrus Chargari Elsa Kalbacher Anne-Lise Gaillard Alexandra Leary Martin Koskas Nicol ás Chopin Anne-Agathe Serre Anne-Claire Hardy-Bessard Ch érif Akladios Fabrice Lecuru Source Type: research

Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : Prise en charge du cancer de l'endomètre métastatique et/ou en rechute
Bull Cancer. 2023 Jun;110(6S):6S34-6S43. doi: 10.1016/S0007-4551(23)00332-6.ABSTRACTRecommendations for clinical practice Nice/Saint-Paul-de-Vence 2022-2023 : Management of advanced/relapsing endometrial cancer Since the first recommendations in 2020 concerning metastatic and/or relapsed endometrial cancer, new treatment options have shown a benefit on patients' life expectancy, justifying their update. In first line, the choice will be made between chemotherapy with carboplatin/paclitaxel or hormone therapy with progestin, depending on tumor characteristics (histological type, grade, expression of hormone receptors, rate ...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: J érôme Alexandre Marie-Aude Le Fr ère-Belda Antoine Angelergues Gwena ël Ferron Isabelle Treilleux Anne-Lise Gaillard Jean-S ébastien Frenel Beno ît You Etienne Rouleau Alain Lortholary Isabelle Ray-Coquard Florence Joly Pour le groupe GINECO Source Type: research

Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : Prise en charge du cancer du col de l'utérus avancé
Bull Cancer. 2023 Jun;110(6S):6S44-6S50. doi: 10.1016/S0007-4551(23)00333-8.ABSTRACTFrench recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2022-2023: Management of advanced cervical cancer The prognosis of cervical cancer remained pejorative until recently, first-line treatment consisting of platinum-based chemotherapy, associated with bevacizumab whenever possible, without any other therapeutic innovation for several years. However in 2022, immunotherapy appeared in the therapeutic landscape. Pembrolizumab can now be prescribed, thanks to the early access status granted by the HAS in September 2022, in pat...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Patricia Pautier Catherine Genestie Laurence Gladieff Jean-Emmanuel Kurtz Alain Lortholary Thibault de La Motte Rouge Anne-Lise Gaillard Anne Ducassou Coraline Dubot Etienne Rouleau Fabrice Narducci Sylvain Demontoy Christophe Hennequin Source Type: research

Prise en charge des carcinomes ovariens de haut grade s éreux et/ou endométrioïdes de stades avancés (III-IV) et testing HRD-BRCA en 2023 : actualisation selon les données publiées et/ou présentées en 2022
Bull Cancer. 2023 Jun;110(6S):6S5-6S9. doi: 10.1016/S0007-4551(23)00329-6.ABSTRACTManagement of high grade, serous and/or endometrioid, advanced (stages III-IV) ovarian carcinomas and HRD-BRCA testing in 2023: update according to data published/presented in 2022 Molecular analysis of ovarian carcinomas must be now systematically performed to determine BRCA1 and BRCA2 status as well as genomic instability score. Several types of tests are available. From a clinical perspective, new data from phase III clinical trials presented in 2022 confirm the key role of PARP inhibitors in first-line medical treatment of high-grade sero...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Fr édéric Selle Florence Joly Laurence Gladieff Karine Prulhi ère Alexandra Leary Elsa Kalbacher Etienne Rouleau Isabelle Ray-Coquard Source Type: research

French recommendations for malignant pheochromocytomas and paragangliomas by the national ENDOCAN-COMETE network
Bull Cancer. 2023 Aug 10:S0007-4551(23)00297-7. doi: 10.1016/j.bulcan.2023.06.002. Online ahead of print.ABSTRACTPheochromocytomas and paragangliomas are rare neuroendocrine tumors, developed respectively in the adrenal medulla and in extra-adrenal locations. Their malignancy is defined by the presence of distant metastases. Forty percent of them are inherited and can be part of different hereditary syndromes. Their management is ensured in France by the multidisciplinary expert centers of the ENDOCAN-COMETE national network "Cancers of the Adrenal gland", certified by the National Cancer Institute and discussed within mul...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Christelle de la Fouchardi ère Magalie Haissaguerre Myriam Decaussin-Petrucci Karine Renaudin Fr éderic Deschamps Eric Miralli é Thibaut Murez Fran çois Pattou Laurence Rocher Pierre-Henri Savoie Matthieu Faron David Taieb Antoine Tabarin J érôme Be Source Type: research

Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : Diagnostic histomoléculaire des carcinomes de l'endomètre
Bull Cancer. 2023 Jun;110(6S):6S10-6S19. doi: 10.1016/S0007-4551(23)00330-2.ABSTRACTFrench recommendations for clinical practice Nice-Saint-Paul de Vence 2022-2023: histomolecular diagnosis of endometrial carcinomas The characterisation of endometrial carcinomas has been recently modified and enriched by molecular classification, the integration of which now impacts therapeutic decisions on whether adjuvant therapy should be administered or not in localized tumors, and influences treatment selection in advanced disease. Mandatory information includes histological type according to WHO 2020 classification, histological grad...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Corinne Jeanne Isabelle Treilleux Marie-Aude Le Fr ère-Belda J érôme Alexandre Florence Joly Etienne Rouleau Source Type: research

Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022 –2023 : prise en charge du cancer de l'endomètre localisé
Bull Cancer. 2023 Jun;110(6S):6S20-6S33. doi: 10.1016/S0007-4551(23)00331-4.ABSTRACTRecommendations for clinical practice, Nice/Saint-Paul-de-Vence 2022-2023: Management of localized endometrial cancer Endometrial cancer is the most frequent gynecological cancers in industrialized countries and its incidence increases. The newmolecularclassification allows determination of the risk of recurrence and helps orienting therapeutic management. Surgery remains the cornerstone of treatment. Minimally invasive approach must be preferred for stages I and II. Surgery includes hysterectomy with bilateral adnexectomy, sentinel lymph n...
Source: Bulletin du Cancer - August 12, 2023 Category: Cancer & Oncology Authors: Alejandra Mart ínez Cyrus Chargari Elsa Kalbacher Anne-Lise Gaillard Alexandra Leary Martin Koskas Nicol ás Chopin Anne-Agathe Serre Anne-Claire Hardy-Bessard Ch érif Akladios Fabrice Lecuru Source Type: research